Interpace Biosciences announced on December 3 2025 that it has fully repaid the $8 million term loan it entered into with BroadOak Capital Partners on October 29 2021. The early repayment eliminates the remaining interest expense on the facility, giving the company a cleaner balance sheet and more cash‑flow flexibility as it concentrates on its thyroid and lung‑cancer diagnostics portfolio.
The loan, which had a three‑year maturity, was originally structured to support Interpace’s growth initiatives. By paying it off ahead of schedule, the company removes a recurring interest obligation—though the exact savings are not disclosed—while demonstrating the strength of its cash position and its ability to service debt without external financing.
The repayment is part of a broader restructuring that began after the company stopped offering its PancraGEN test on May 2 2025, following the loss of Medicare reimbursement. In the most recent quarter, Interpace reported revenue of $8.756 million, down from $12.295 million a year earlier, and net income of $911 k versus $1.676 million in the same period last year. The company’s focus has shifted to its high‑margin thyroid and lung‑cancer diagnostics, where it has seen record test volumes and revenue growth.
CFO Chris McCarthy said the debt retirement “strengthens our balance sheet and positions us to focus our full resources on driving commercial growth of our thyroid tests.” CEO Tom Burnell added that the move “positions us to focus our full resources on driving commercial growth as we continue to deliver record testing volumes and revenue for our thyroid tests.”
By removing the debt burden, Interpace can allocate capital to its core growth areas, reduce financial risk, and support ongoing investments in its diagnostic platform. The early repayment signals confidence in the company’s cash‑flow generation and underscores its commitment to a lean, high‑margin business model moving forward.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.